Active, not recruitingPHASE2, PHASE3NCT03913143
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
Studying Leber congenital amaurosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ProQR Therapeutics
- Principal Investigator
- ProQR Medical MonitorProQR Therapeutics
- Intervention
- sepofarsen(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2019 – 2023
Study locations (14)
- University of Iowa, Iowa City, Iowa, United States
- Universitair Ziekenhuis Gent (UZ), Ghent, Belgium
- INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
- Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP), São Paulo, São Paulo, Brazil
- The Hospital for Sick Children - SickKids, Toronto, Ontario, Canada
- McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada
- Centre de maladies rares CHNO des Quinze Vingt, Paris, France
- Hospital Civil de Strasbourg, Strasbourg, France
- Justus-Liebig Universität - Department of Ophthalmology, Giessen, Germany
- University of Tuebingen - Inst. for Ophthalmic Research, Tübingen, Germany
- Eye Clinic University of Campania Luigi Vanvitelli, Naples, Italy
- Amsterdam University Medica Center - Locatie AMC, Amsterdam, Netherlands
- Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands
- Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03913143 on ClinicalTrials.govOther trials for Leber congenital amaurosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06891443Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)Laboratoires Thea
- RECRUITINGPHASE1, PHASE2NCT05906953Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)HuidaGene Therapeutics Co., Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06088992Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03920007Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DAtsena Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT00999609Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisSpark Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01208389Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Spark Therapeutics, Inc.